SCHEDULE 13G/A 0001415889-24-029979 0001699737 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 06/30/2025 0001583648 Palvella Therapeutics, Inc. 697947109 125 Strafford Ave, Suite 360 Wayne PA 19087 Rule 13d-1(c) Samsara BioCapital, L.P. b DE 0.00 339743.00 0.00 339743.00 339743.00 3.1 PN Samsara BioCapital GP, LLC b DE 0.00 339743.00 0.00 339743.00 339743.00 3.1 OO Srinivas Akkaraju b X1 0.00 339743.00 0.00 339743.00 339743.00 3.1 IN Palvella Therapeutics, Inc. 125 Strafford Ave, Suite 360, Wayne, PA, 19087. The names of the persons filing this report (collectively, the "Reporting Persons") are: Samsara BioCapital, L.P. ("Samsara LP") Samsara BioCapital GP, LLC ("Samsara GP") Srinivas Akkaraju ("Dr. Akkaraju") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301 Samsara LP Delaware Samsara GP Delaware Dr. Akkaraju United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Samsara LP directly holds 339,743 shares of common stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is a managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. The percentage set forth in each row 11 is based upon 11,055,665 shares of common stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement, dated as of December 20, 2024 (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on December 20, 2024). Samsara BioCapital, L.P. /s/ Srinivas Akkaraju 08/14/2025 Samsara BioCapital GP, LLC /s/ Srinivas Akkaraju 08/14/2025 Srinivas Akkaraju /s/ Srinivas Akkaraju 08/14/2025